Published On: Wed, Sep 14th, 2016

Research Analysts’ Recent Ratings Updates for Horizon Pharma (HZNP)

Several analysts have recently updated their ratings and price targets for Horizon Pharma (NASDAQ: HZNP):

9/13/2016 – Horizon Pharma had its price target raised by analysts at Mizuho from $30.00 to $33.00. They now have a “buy” rating on the stock.
9/13/2016 – Horizon Pharma had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $30.00 price target on the stock.
9/12/2016 – Horizon Pharma was given a new $24.00 price target on by analysts at Morgan Stanley. They now have a “hold” rating on the stock.
9/12/2016 – Horizon Pharma had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $42.00 price target on the stock.
9/12/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Brean Capital. They now have a $32.00 price target on the stock.
9/8/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Jefferies Group.
9/8/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc.. They now have a $27.00 price target on the stock.
8/23/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $30.00 price target on the stock.
8/11/2016 – Horizon Pharma was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Horizon’s second-quarter results were impressive with both earnings and revenues increasing year over year. Performance of the company’s business units – Orphan, Primary Care, and Rheumatology – continues to be impressive. We are positive on the company’s growth-by-acquisition strategy, through which it actively pursues acquisitions to expand and diversify its portfolio. We could see more of such merger & acquisition activities in the orphan and specialty space. Moreover, the Hyperion and Crealta acquisitions, which are expected to strengthen Horizon’s position in the orphan disease market, bode well. Horizon is working on label expansion of Actimmune and Ravicti, if approved for additional indications, would be commercially significant. Acquisition of global rights to Actimmune would be a positive too. However, the subpoena and charges brought on by Express Scripts will remain an overhang on the stock.”
8/10/2016 – Horizon Pharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $25.00 price target on the stock. According to Zacks, “Horizon’s second-quarter results were good with both earnings and revenues increasing year over year. Performance of the company’s business units – Orphan, Primary Care, and Rheumatology – continues to be impressive. We are positive on the company’s growth-by-acquisition strategy, through which it actively pursues acquisitions to expand and diversify its portfolio. We could see more of such merger & acquisition activities in the orphan and specialty space. Moreover, the Hyperion and Crealta acquisitions, which are expected to strengthen Horizon’s position in the orphan disease market, bode well. Horizon is working on label expansion of Actimmune and Ravicti, if approved for additional indications, would be commercially significant. Acquisition of global rights to Actimmune would be a positive too. However, the subpoena and charges brought on by Express Scripts will remain an overhang on the stock.”
8/10/2016 – Horizon Pharma had its “overweight” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $33.00 price target on the stock, down previously from $34.00.
8/10/2016 – Horizon Pharma had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $30.00 price target on the stock, up previously from $29.00.
8/10/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $30.00 price target on the stock, up previously from $24.00.
8/9/2016 – Horizon Pharma had its price target raised by analysts at Citigroup Inc. from $18.00 to $21.00. They now have a “neutral” rating on the stock.
8/9/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Brean Capital. They now have a $30.00 price target on the stock.
8/4/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $27.00 price target on the stock. They wrote, “Q2 results were well ahead of consensus (revs +10%, EPS +11%), driven by stronger revs from primary care products (+$19M vs JEF). This outperformance came despite higher than forecasted expenses (+$7M vs JEF). Mgt also reaffirmed its FY16 guidance – which appears increasingly achievable as improved GtN’s offset softening PCP Rxs.””
8/3/2016 – Horizon Pharma had its “outperform” rating reaffirmed by analysts at Mizuho. They now have a $24.00 price target on the stock.
8/3/2016 – Horizon Pharma had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $29.00 price target on the stock.
8/2/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Brean Capital. They wrote, “We valued Mallinckrodt via discounted cash flow analysis. We assigned the company an 11% weighted average cost of capital, since we view its commercial risk as manageable. We utilize a 2% terminal growth rate since the company has durable assets and is investing further in its pipeline.””
8/1/2016 – Horizon Pharma had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $30.00 price target on the stock.

Horizon Pharma Inc. (NASDAQ:HZNP) traded up 2.40% during mid-day trading on Wednesday, hitting $19.62. The stock had a trading volume of 3,042,170 shares. The company has a 50-day moving average of $20.22 and a 200-day moving average of $17.50. Horizon Pharma Inc. has a 12-month low of $12.86 and a 12-month high of $32.34. The firm’s market cap is $3.16 billion.
Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.12. The business had revenue of $257.40 million for the quarter, compared to analyst estimates of $235.43 million. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The business’s quarterly revenue was up 48.9% on a year-over-year basis. During the same period last year, the company posted $0.39 EPS. Analysts expect that Horizon Pharma Inc. will post $2.16 earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/14/research-analysts-recent-ratings-updates-for-horizon-pharma-hznp.html

In related news, EVP Jeffrey W. Sherman sold 2,900 shares of the stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total value of $58,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.10% of the stock is owned by corporate insiders.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Receive News & Ratings for Horizon Pharma Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Horizon Pharma Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>